/
Other
Randomized
41
Pipeline Programs↗
38
Active Trials↗
74
Companies Involved↗
Randomized is a moderately active landscape with 41 programs across 74 companies. The most active players are Gilead, Sustained Therapeutics Inc., Beam Therapeutics. 9 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 15
Phase 215
Phase 39
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
37 of 40 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 40 classified programs, each share of the total. Modality classified for 100% of 41 pipeline programs.
Analysis
Trial Status
382
clinical trials
Completed265 · 69%
Terminated30 · 8%
Unknown status30 · 8%
Recruiting19 · 5%
Withdrawn18 · 5%
Not yet recruiting10 · 3%
Other10 · 3%
Clinical Trials
Trial Activity
382 trials
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Recruiting·—·Phase 2·NCT06700798·90 enrolled
Page 1 of 26
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)